Details of the Drug Combinations

General Information of This Drug (ID: DMAQ2LK)

Drug Name

Teicoplanin DMAQ2LK

Synonyms

Targocid (TN)

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
Skin infection	1F28-1G0Z	Investigative	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Teicoplanin + Ruxolitinib	DC4GQ1G	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
------------------------------------------------------------------------------------

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Vancomycin + Teicoplanin	DCTKWFZ	Vancomycin	Skin Diseases, Infectious	[4]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). Expert Rev Anti Infect Ther. 2020 May;18(5):415-422.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4	ClinicalTrials.gov (NCT00430937) Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections